))
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Equillium’s 8K filing here.
About Equillium
Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.
Further Reading
- Five stocks we like better than Equillium
- Top Stocks Investing in 5G Technology
- From PACs to Portfolios: Billionaire Bets and Investor Reactions
- How to buy stock: A step-by-step guide for beginnersÂ
- AppLovin Stock Quadruples: What’s Behind the Bullish Sentiment?
- The How and Why of Investing in Gold Stocks
- Battle of the Retailers: Who Comes Out on Top?
